



## CLAIMS

Sub C 7  
5  
1. Derivatives of propionic acid, 1-(p-chlorobenzoyl)  
-5- methoxy-2-methyl -3-indolylacetic acid, 5-benzoyl  
-1,2-dihydro -3H- pyrrolo[1,2-a]pyrrole -1-carboxylic  
acid, 6-methoxy -2-naphthylacetic acid, characterized  
in that they have the following general formula:




where:


A and B are chosen among hydrogen, linear or branched,  
substituted or non substituted alkyl chains, M is  
15 chosen among:




(XXX)



(XXXI)




(XXXII)




(XXXIII)


where R is chosen among:



(II)




(X)



(III)


Y is chosen among oxygen, NH, NR<sub>1</sub>, where R<sub>1</sub> is a linear or branched alkyl group, and n is comprised between 1 and 10.

2. Nitric esters according to claim 1, <sup>wherein</sup> ~~characterized in~~  
that the fragment:




is a linear, branched or cyclic alkylenic group C<sub>2</sub>-C<sub>10</sub>.

3. Derivative of propionic acid according to claim 1,  
characterized in that M is equal to



(XXXIII)


where R is:



(II)


A and B are equal to hydrogen, Y is equal to oxygen,  
and n is equal to four.

4. Derivative of propionic acid according to claim 1,  
characterized in that M is equal to



(XXXIII)


where R is:



(II)


A and B are equal to hydrogen, Y is equal to NH, and n is equal to four.

5. Derivatives of propionic acid according to claim 1, characterized in that M is equal to



(XXXIII)


where R is equal to:



(III)


Y is equal to oxygen, A and B are equal to hydrogen, and n is equal to four.

6. Derivative of propionic acid according to claim 1, characterized in that M is equal to



(XXXIII)

where R is equal to:




(III)

5


Y is equal to NH, A and B are equal to hydrogen, and n is equal to four.

7. Derivative of propionic acid, according to claim 1, characterized in that M is equal to



(XXXIII)


15 where R is equal to



(X)

20 A and B are equal to hydrogen, y is equal to oxygen and n is equal to four.

8. Derivative of propionic acid according to claim 1, characterized in that M is equal to




(XXXIII)

25

Jkm  
02/27/98

where R is equal to,



(X)


5

A and B are equal to hydrogen, Y is equal to NH and n is equal to four.

D 3.1. <sup>Compounds</sup> ~~Derivatives~~ of 5-benzoyl -1,2-dihydro-3H-pyrrolo[1,2-a] pyrrole -1-carboxylic acid according to

D 10 <sup>wherein</sup> ~~characterized in that~~ M is equal to

T310X



(XXX)


—15—

A and B are equal to hydrogen, Y is equal to oxygen and n is equal to four.

D 4.1. <sup>Compounds</sup> ~~Derivatives~~ of 1-(p- chlorobenzoyl) -5-methoxy - 2-methyl-3-indolylacetic acid according to claim 1,

D 20 <sup>wherein</sup> ~~characterized in that~~ M is equal to

T311X



(XXXII)

25

A and B are equal to hydrogen, Y is equal to oxygen and

Jkm  
02/27/98

n is equal to four.


11. Nitric esters according to claim 1, characterized in that they are utilizable in the pharmaceutical field as anti-inflammatory agents.

5 12. Nitric esters according to claim 1, characterized in that they are utilizable in the pharmaceutical field as analgesic agents.

13. Nitric esters according to claim 1, characterized in that they are utilizable in the treatment of rheumatic illnesses, in the treatment of disorders of an immunologic nature and of the moderate to medium painful states.


14. Nitric esters according to claim 1, characterized in that they are utilizable in the treatment of the diseases of the cardiovascular system, in the treatment of senile dementia, in the treatment of myocardial and brain ischemiae and in cases of arterial thrombosis.

15. Process for the preparation of nitric esters according to claim 1 and having the following general formula:




25 where A and B are chosen among hydrogen, linear or branched, substituted or non substituted alkyl chains,


M is chosen among




(XXX)



(XXXI)




(XXXII)




(XXXIII)


where R is chosen among:



(II)




(III)



(X)


Y is chosen among oxygen, NH, NR<sub>1</sub>, where R<sub>1</sub> is a linear or branched alkyl group, and n is comprised between 1 and 10, characterized in that it comprises the following steps:

- 10 - Preparation of sodium salt of derivatives having the following general formula:




(VIA)

where M is chosen among (XXX), (XXXI), (XXXII),




(XXXIII)


20 where R is chosen among the following structures:



(II)




(III)



(X)

or preparation of derivatives (VIA) functionalized to the carboxylic group, such as acyclic chlorides, anhydrides or the like;

- Reaction between the sodium salt of said derivatives (VIA) or of said derivatives (VIA) functionalized to the carboxylic group, with a compound having the following general formula:




(VII)

where:

$R_4$  is chosen among chlorine, bromine,  $NHR_5$  with  $R_5$  hydrogen, linear or branched alkyl chain, A and B are chosen among hydrogen, linear or branched, substituted or non substituted alkyl chains,  $R_3$  is chosen among chlorine, bromine and iodine, and n is comprised between 1 and 10, with ensuing production of the relevant monomeric esters or the relevant amides;


- Reaction of said monomeric esters or said amides with a nitrating agent such as  $AgNO_3$  or the like, with ensuing production of nitric esters (IA).

16. Process for the preparation of nitric esters according to claim 1 and having the following general formula:




where:


A and B are chosen among hydrogen, linear or branched, substituted or non substituted alkyl chains, M is chosen among




(XXX)



(XXXI)




(XXXII)



(XXXIII)


5

where R is chosen among:




(X)

10



(II)

15




(III)

20

Y is chosen among oxygen, NH, NR<sub>1</sub>, where R<sub>1</sub> is a linear or branched alkyl group, and n is comprised between 1 and 10, characterized in that it comprises the following steps:

- Preparation of sodium salt of derivatives having the following general formula:




(VIA)

25

where M is chosen among (XXX), (XXXI), (XXXII),


5



(XXXIII)


where R is chosen among the following structures:

10




(II)

15



(X)




(III)

or preparation of derivatives (VIA) functionalized to the carboxylic group, such as acyclic chlorides, anhydrides or the like;

- Reaction between the sodium salt of said derivatives (VIA) or of said derivatives (VIA) functionalized to the carboxylic group, with a composition having the following general formula:

25



(VIII)

where:

$R_4$  is chosen among chlorine, bromine,  $NHR_5$  with  $R_5$  hydrogen, linear or branched alkyl chain, A and B are chosen among hydrogen, linear or branched, substituted or non substituted alkyl chains, and n is comprised between 1 and 10, with ensuing production of the relevant monomeric esters or the relevant amides;

- Reaction of said monomeric esters or said amides with an halogenating compound such as  $PBr_3$  or the like, with ensuing production of said monomeric esters or said amides, characterized by the presence of a terminal halogen group;

- Reaction of said monomeric esters or of said amides, characterized by the presence of a terminal halogen group with a nitrating agent such as  $AgNO_3$  or the like, with ensuing production of nitric esters (IA).

17. Pharmaceutical compositions having anti-inflammatory activity characterized in that they comprise at least one nitric ester according to claim 1 as active constituent.

18. Pharmaceutical compositions having analgesic activity characterized in that they comprise at least one nitric ester according to claim 1 as active constituent.